TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Acid exposure to the distal esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of soluble Ve-cadherin and antibody VE-cadherin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: readmission to hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Ipsilateral excitability ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of neo-adjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of neo-adjuvant chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Recent Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with decreased myocardial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with increased coronary plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rotator cuff healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Combined Device
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Symptom Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Month Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain changes assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for Alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Triglycerides percentage change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Segmental Lordosis Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disc Height Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KOOS-4 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HAM-D17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-insertion rate of urinary catheter after removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rate of molecular remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NRS Average Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants showing CR/PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Sedation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Quality of fluorescence-videoangiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival (Based On All-Cause Mortality)
Endpoint domain: Mortality/survival
Primary endpoint: graft-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: changes in pelvic organ prolapse-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance with Doppler measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Draize toxicity assessment score
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cmax of GLPG1205
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of GLPG1205
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of GLPG1205
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of GLPG1205
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in verbal communication
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Geometric mean titers (GMT) of hemagglutination inhibition (HI) antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Smoking cessation behavior
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: discharge time shortening
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient Health Questionnaire 9 (PHQ9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder 7 (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Panic Disorder Severity Scale-Self Report (PDSS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Treatment-Emergent Deaths of All Causes
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Major Bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: MACBIS50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean RGB values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Who Received Influenza Vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent of patients eligible for quality measures (ABCS)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Western Ontario & Mc-master Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and efficacy of Clopidogrel plus aspirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of hospitalization due to heart failure worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Use of mechanical left ventricle support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Non-responder Patients Who Converted to Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Attending at Least One Outpatient Visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gestational age of delivery
Endpoint domain: Mortality/survival
Primary endpoint: Number of device malfunctions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Interferometric Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of radioactivity eliminated in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of radioactivity eliminated in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics (PK) of total radioactivity: peak plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence to psychiatric rehabilitation services
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Occurrence of adverse clinical, biochemical or haematological events
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With DAS28 Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of premature menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tmax (hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC (0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of rhTPO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicities associated with rhTPO
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of CBD Stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of specific bacterial and/or fungal pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Glucose level for counter-regulatory hormone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Temperature at supraclavicular region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cooperation Rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Circumferential resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Symptomatic recurrent VTE
Endpoint domain: Mortality/survival
Primary endpoint: Correlations between SLN location and clinical-pathological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of treatment more than 4 hr. per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plaque instability detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of omalizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in performance time on Jebsen Taylor Hand Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average of Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline EORTC
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline dysphagia scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Grade II-IV Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Regional Cerebral Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: All-cause mortality to Day 90
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in log10 Hepatitis C Virus RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients with partial clearance of AK lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUC Last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Oral Bioavailability (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blastocyst ploidy outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive conversion rate of Muv hemagglutination inhibition antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive conversion rate of Muv neutralization antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants free from initiating conventional anti-CMV treatment by Day+100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Modified Constant scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of images from breast biopsy specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the percentage of volume of lipid rich necrotic core (LRNC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial precursor cell account (EPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Proviral DNA in PBMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Share of LEJR admissions discharged to institutional Post-Acute Care (PAC)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Investigator Overall Satisfaction With the Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum uric acid value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Tregs number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC From Day 90 To Day 180 Based on Percent Change From Baseline in 24-Hour Uox
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody Concentrations Against Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Amount of N-acetylamantadine excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic conclusion of SPECT V/Q scans for acute PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hgb at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change in Modified Rodnan Skin Score (mRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cmax of plasma salmeterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of plasma fluticasone propionate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma salmeterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of plasma fluticasone propionate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of AZD2171
Endpoint domain: Adverse events/effects
Primary endpoint: Magnetic Resonance Image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Any Complication Requiring Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Overall Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 5-HIAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma 5-HIAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in pain density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Cumulative Fentanyl Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, myocardial infarction, retransplantation, and heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Decrease of left ventricular ejection fraction of at least 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Exercise Capacity (6MWT Distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Equivalence of Auscul-X to digital stethoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Eosinopenia as a sepsis marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrent fatal or nonfatal VTE
Endpoint domain: Mortality/survival
Primary endpoint: Change in lung clearance index (LCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: fMRI signals in parietal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain White Matter Volume for Patients Versus Sibling Controls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Methylphenidate (MPH) Home Maintenance Phase Baseline to Completion of Phase as Measured by Conners' Teacher Rating Scale (CTRS: ADHD T Score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Reading: Composite Standard Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Blood lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: elbow flexion strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walk speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tongue Preservation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of SARS-CoV-2 -infected patients
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of PeaPod compared with Anthropometry and BIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen saturation ≥90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aβ-specific antibody titre in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Patients With Extubation Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Preferred physical characteristics of a vaginal film product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S100B protein serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCss (Area Under the Plasma Concentration-time Curve During a 7-day Dosing Interval at Steady State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,av (Average Plasma Concentration During a Dosing Interval at Steady State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,Max (Maximum Observed Plasma Concentration During a Dosing Interval at Steady State)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index of the offsprings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Maternal gestational weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in maternal quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain NVS Construct Measure (Composite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral perfusion (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amputation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Rehospitalization incidence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage SIGH SAD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-Form Health Survey (SF-12) Physical Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short-Form Health Survey (SF-12) Mental Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postsurgical Patient Satisfaction Questionnaire (PSPSQ)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes